BioScrip Inc. (NASDAQ:BIOS) CFO Jeffrey M. Kreger bought 10,000 shares of the stock in a transaction dated Friday, November 11th. The stock was bought at an average price of $1.32 per share, with a total value of $13,200.00. Following the purchase, the chief financial officer now owns 22,628 shares of the company’s stock, valued at approximately $29,868.96. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link.

Shares of BioScrip Inc. (NASDAQ:BIOS) opened at 1.39 on Wednesday. The firm’s 50-day moving average price is $2.69 and its 200-day moving average price is $2.66. BioScrip Inc. has a 52 week low of $1.15 and a 52 week high of $3.43. The firm’s market cap is $163.58 million.

BioScrip (NASDAQ:BIOS) last released its quarterly earnings data on Monday, November 7th. The company reported ($0.12) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.05) by $0.07. The company earned $224.50 million during the quarter, compared to analysts’ expectations of $223.26 million. The company’s revenue was down 9.2% on a year-over-year basis. During the same period last year, the firm posted ($0.38) earnings per share. Equities research analysts expect that BioScrip Inc. will post ($0.39) EPS for the current fiscal year.

Several hedge funds have recently made changes to their positions in BIOS. Metropolitan Life Insurance Co. NY bought a new stake in shares of BioScrip during the second quarter worth $152,000. BlackRock Advisors LLC boosted its position in BioScrip by 87.8% in the third quarter. BlackRock Advisors LLC now owns 57,715 shares of the company’s stock valued at $167,000 after buying an additional 26,989 shares in the last quarter. Oxford Asset Management acquired a new position in BioScrip during the second quarter valued at $176,000. PNC Financial Services Group Inc. raised its position in shares of BioScrip by 368.4% in the second quarter. PNC Financial Services Group Inc. now owns 74,362 shares of the company’s stock valued at $190,000 after buying an additional 58,486 shares in the last quarter. Finally, M&T Bank Corp purchased a new position in shares of BioScrip during the second quarter valued at about $204,000. 85.85% of the stock is owned by institutional investors.

A number of equities research analysts have recently issued reports on the company. Zacks Investment Research lowered BioScrip from a “buy” rating to a “hold” rating in a research note on Friday, August 12th. Jefferies Group initiated coverage on BioScrip in a research note on Tuesday, November 8th. They issued a “buy” rating and a $2.50 target price for the company.

About BioScrip

BioScrip, Inc is engaged in providing infusion solutions. The Company partners with physicians, hospital systems, skilled nursing facilities, healthcare payors and pharmaceutical manufacturers to provide patients access to post-acute care services. The Company operates through Infusion Services segment.

5 Day Chart for NASDAQ:BIOS

Receive News & Stock Ratings for BioScrip Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BioScrip Inc. and related stocks with our FREE daily email newsletter.